APC11 inhibitors belong to a distinctive class of chemical compounds that primarily target the Anaphase-Promoting Complex Subunit 11 (APC11), a crucial component of the ubiquitin-proteasome system (UPS). The UPS is a finely regulated cellular pathway responsible for the degradation of proteins, orchestrating key processes such as cell cycle progression, signal transduction, and maintenance of cellular homeostasis. Within the APC/C complex, APC11 functions as an E3 ligase, facilitating the transfer of ubiquitin moieties onto specific substrates marked for degradation. The enzymatic activity of APC11 plays a pivotal role in the temporal regulation of cell cycle transitions by targeting specific proteins for degradation during distinct phases. Inhibitors designed to selectively modulate APC11 activity can potentially exert influence over the progression of cell division and related cellular functions.
APC11 inhibitors often comprise small molecules with specific binding motifs that interact with the catalytic site of APC11, impeding its ubiquitination activity. By disrupting the normal function of APC11, these inhibitors can alter the dynamics of protein degradation within the cell, thereby impacting critical cellular processes. The development of APC11 inhibitors represents a significant area of research in the broader field of cell biology andwith the aim of unraveling the intricacies of the UPS and its regulatory mechanisms.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib inhibits the 26S proteasome, leading to an accumulation of proteins and potentially interfering with APC/C's function. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is a proteasome inhibitor that can prevent the degradation of ubiquitinated proteins, indirectly affecting APC11's role in protein turnover. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin is a selective proteasome inhibitor that can disrupt the degradation of cell cycle regulatory proteins, indirectly affecting APC11 activity. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
Carfilzomib is an epoxyketone-based proteasome inhibitor that can inhibit the chymotrypsin-like activity of the proteasome, affecting APC11's role in the cell cycle. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is a specific inhibitor of the proteasome that can block the degradation of ubiquitinated proteins, thereby potentially affecting APC11-mediated proteolysis. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
MLN4924 inhibits the NEDD8-activating enzyme, which is necessary for cullin-RING ligase function, possibly affecting APC11's associated complexes. | ||||||
IU1 | 314245-33-5 | sc-361215 sc-361215A sc-361215B | 10 mg 50 mg 100 mg | $138.00 $607.00 $866.00 | 2 | |
IU1 selectively inhibits the deubiquitinating enzyme USP14, which can enhance the degradation of ubiquitin-proteasome substrates, thereby potentially influencing APC11 activity. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oprozomib is an bioavailable proteasome inhibitor that can affect the degradation pathway of APC11's ubiquitin-proteasome system. | ||||||
Withaferin A | 5119-48-2 | sc-200381 sc-200381A sc-200381B sc-200381C | 1 mg 10 mg 100 mg 1 g | $130.00 $583.00 $4172.00 $20506.00 | 20 | |
Withaferin A is a steroidal lactone that has been shown to disrupt proteasomal activity, which may indirectly influence APC11's role in cell cycle regulation. | ||||||